Evoke Pharma (NASDAQ:EVOK) and EVERSANA have presented real-world data demonstrating that GIMOTI, a nasal spray for treating diabetic gastroparesis (DGP), reduces healthcare costs compared to oral metoclopramide. The data, presented at the American College of Gastroenterology 2023 Annual Meeting, shows that DGP patients treated with GIMOTI were less likely to visit the emergency department or be admitted to the hospital. Over a six-month period, GIMOTI patients spent approximately $15,000 less than those on oral metoclopramide.